HeartRhythm

MARCH 10, 2025

Ablation index (AI)-guided pulmonary vein isolation (PVI) has enhanced procedural outcomes for atrial fibrillation (AF).1 1 However, patients with persistent AF present higher recurrence rates due to advanced atrial remodeling,2-3 represented by the left atrial low voltage area (LVA), compared to those with paroxysmal AF.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Pulmonary 40

DAIC

JANUARY 30, 2025

a powerful and advanced mechanical thrombectomy system for the removal of venous thrombus and the treatment of pulmonary embolism (PE), effectively completing Penumbras VTE platform. Innovative Valve Technology Element features the HemoLockValve System, designed to ensure hemostasis through dual-valve engineering. CAT TM 16 catheter.

Technology 52

Technology Anatomy Embolism Innovation 52

DAIC

SEPTEMBER 4, 2024

The pivotal trial will study the Vertex Pulmonary Embolectomy System, which incorporates Jupiter’s Endoportal Control platform technology into an endovascular procedure intended to treat Acute Pulmonary Embolism (PE) with an unprecedented level of control and precision. pivotal study (NCT06576427).

Pulmonary 52

Pulmonary Embolism Technology Anatomy 52

Frontiers in Cardiovascular Medicine

DECEMBER 23, 2024

BackgroundPercutaneous mechanical thrombectomy (PMT) is increasingly used in the treatment of intermediate and high-risk acute pulmonary embolism (PE), and the treatment of high-risk PE with the aid of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has also been reported. The mortality rate was 27.3% during the 90-day follow-up.

Embolism 52

Embolism Pulmonary Cardiac Arrest Biomarkers 52

DAIC

JULY 31, 2024

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, reported it has submitted a 510(k) for approval of its patented Morph DNA Steerable Introducer Sheath. mtaschetta-millane Wed, 07/31/2024 - 07:00 July 31, 2024 — BioCardia, Inc. ,

Myocardial Infarction 99

Myocardial Infarction Technology Angina Pulmonary 99

Frontiers in Cardiovascular Medicine

MAY 1, 2024

BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Pulmonary Technology 52

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Background Percutaneous pulmonary valve implantation (PPVI) has emerged as a less invasive alternative for treating severe pulmonary regurgitation after tetralogy of Fallot (TOF) repair in patients with a native right ventricular outflow tract (RVOT).

Pulmonary 49

Pulmonary Heart Valves Innovation Technology 49

DAIC

JUNE 4, 2024

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10. Scientists Suggest a New Method for Diagnosing Heart Diseases 6.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

DAIC

JUNE 13, 2024

Xeltis synthetic restorative pulmonary heart valve evolves into a fully functioning, natural heart valve through colonization by the patient’s own tissue. Xeltis’ novel technology has already treated over 100 patients across different clinical trials.

Heart Valves 111

Heart Valves Technology Pulmonary Outcomes 111

HeartRhythm

MARCH 31, 2025

The TWOSOME trial randomized paroxysmal atrial fibrillation (AF) patients to either single-tip or single shot pulsed field ablation (PFA) for pulmonary vein isolation (PVI). Only few data investigating silent cerebral lesions (SCL) after novel PFA technology exist.

40

40

HeartRhythm

MARCH 31, 2025

Conduction delay or isolation of the superior vena cava (SVC) has been previously described during the right superior pulmonary vein (RSPV) ablation using thermal ablation technologies due to the anatomical proximity of the SVC to the RSPV. Currently, there are no reports on the impact of pulsed-field ablation (PFA) on the SVC.

40

40

HeartRhythm

MARCH 31, 2025

Pulsed Field Ablation (PFA) represents a significant advancement in ablation technology for pulmonary vein isolation (PVI). However, the durability of chronic ablation regions created by the Novel Variable-Loop Circular Catheter (VLCC, VARIPULSE) remains unclear.

40

40

HeartRhythm

MARCH 31, 2025

Non-thermal pulsed field ablation (PFA) is an emerging technology to perform pulmonary vein isolation (PVI) for atrial fibrillation (AF). Different PFA systems are available, but no comparative outcome data exist.

40

40

DAIC

JULY 17, 2024

a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases announced that the Unites States Patent Office has granted Patent No: 12,036,371 titled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035.

Myocardial Infarction 105

Myocardial Infarction Atrial Fibrillation Technology Angina 105

Journal of the American Heart Association

MARCH 8, 2024

BackgroundIn recent years, self‐expanding technology to treat pulmonary regurgitation in the native right ventricular outflow tract became Food and Drug Administration approved in the United States and is now routinely used. This paves the way for routine use of VR in patient selection for self‐expanding valve technologies.

Pulmonary 45

Pulmonary Technology Congenital Hospital 45

HeartRhythm

MARCH 31, 2025

In patients with atrial fibrillation (AF), pulsed field ablation (PFA) has emerged as a safe and effective technique for pulmonary vein isolation (PVI). However, first-generation PFA catheters lack integration with 3D mapping technology, meaning fluoroscopy remains the primary method for catheter guidance during PFA-PVI procedures.

40

40

HeartRhythm

AUGUST 21, 2024

No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrial fibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation.

Anatomy 40

Anatomy Atrial Fibrillation Pulmonary Ablation 40

HCPLive

SEPTEMBER 30, 2024

The latest episode of Lungcast explores the evolving field of pulmonary imaging technology and the transformative impact of artificial intelligence.

Technology 59

Technology Pulmonary 59

Frontiers in Cardiovascular Medicine

MAY 12, 2024

BackgroundAcute pulmonary embolism (APE) is a common and potentially fatal cardiovascular disease that can lead to sudden cardiac arrest in severe cases. For patients with concurrent main pulmonary artery embolism and bleeding, balloon pulmonary angioplasty may be an option.

Embolism 40

Embolism Pulmonary Hemorrhage Cardiac Arrest 40

HeartRhythm

MARCH 31, 2025

The AP Fontan operation and the total cavo-pulmonary connection (TCPC) have revolutionised the surgical treatment of patients with functionally univentricular hearts. However, post-surgical arrhythmias contribute considerably to morbidity and mortality and can be difficult to manage.

40

40

HeartRhythm

APRIL 30, 2024

Cryoballoon (CB) ablation is the mainstay of single-shot pulmonary vein isolation (PVI). However, these two technologies have not been compared. A radiofrequency balloon (RFB) catheter has recently emerged as an alternative.

Pulmonary 40

Pulmonary Ablation Technology Outcomes 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) has recently been introduced as a novel ablation technology for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). High rates of acute PVI have been observed based on electrograms of the PFA device only.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Technology 40

DAIC

JANUARY 31, 2024

A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e.,

Ablation 111

Ablation Atrial Fibrillation Anatomy Pulmonary 111

DAIC

MARCH 26, 2024

Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians. CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI

Embolism 105

Embolism Pulmonary Blood Clot Cancer 105

HeartRhythm

MARCH 31, 2025

Pulmonary vein isolation (PVI) is the most effective means of maintaining sinus rhythm in atrial fibrillation (AF); point-by-point radiofrequency (RF) catheter ablation is a widely used approach to PVI. While complications are rare with both technologies, the risk of atrioesophageal fistula (AEF) remains a concern.

40

40

HeartRhythm

APRIL 30, 2024

Non-thermal pulsed field ablation (PFA) is an novel technology to perform pulmonary vein isolation (PVI) for atrial fibrillation (AF). Different PFA systems are available, but no comparative data exist.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation Technology 40

HeartRhythm

APRIL 30, 2024

Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF). Advances in catheter technology, ablation techniques, and ablation lesion metrics have resulted in improved PV isolation durability. PV reconnection is the most common cause of recurrent AF following an ablation procedure.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Technology 40

Journal of Cardiovascular Electrophysiology

FEBRUARY 20, 2025

Methods In this study, blood samples were collected from 16 patients before and 24h after pulmonary vein isolation (PVI) via a novel investigational PFA-based technology.

Biomarkers 40

Biomarkers Pulmonary Technology Ablation 40

Journal of Cardiovascular Electrophysiology

MARCH 3, 2024

Abstract Introduction Through systematic scientific rigor, the CLOSE guided workflow was developed and has been shown to improve pulmonary vein isolation durability. However, this technique was developed at a time when using power-controlled ablation catheters with conventional power ranges was the norm.

Ablation 40

Ablation Pulmonary Technology Outcomes 40

HeartRhythm

MARCH 31, 2025

Persistent atrial fibrillation (AF) ablation targeting extra-pulmonary vein drivers using various technologies has delivered varying results from no benefit to significant arrhythmia free survival.

40

40

Journal of the American Heart Association

MARCH 13, 2025

BackgroundResearch into the gutlung axis links gut microbiota to pulmonary artery hypertension (PAH). Our findings have implications for advancing gut microbiotabased PAH diagnostic technologies and targeted therapies. Journal of the American Heart Association, Ahead of Print.

Pulmonary 40

Pulmonary Hypertension Technology 40

HeartRhythm

MARCH 31, 2025

The integration of 3D mapping technology, which allows detailed visualization of multielectrode ablation catheters and mapping of the left atrium and pulmonary veins, is anticipated to improve clinical outcomes. The application of pulsed field energy for atrial fibrillation (AF) has seen rapid advancements in recent years.

40

40

DAIC

JUNE 7, 2024

a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced that the Unites States Patent Office has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a patent term that will expire in 2036. Peter Altman , BioCardia CEO.

Hospital 111

Hospital Technology Pulmonary Stroke 111

HeartRhythm

MARCH 31, 2025

Pulsed field ablation (PFA) has emerged as a new ablation method for treating atrial fibrillation (AF) through pulmonary vein isolation (PVI).

40

40

HeartRhythm

MARCH 31, 2025

Pulsed field ablation (PFA) has emerged as a promising energy for pulmonary vein isolation (PVI). Advancements in next generation PFA technologies and waveforms are needed.

40

40

HeartRhythm

MARCH 31, 2025

Pulsed field ablation (PFA) represents a novel technology for the treatment of atrial fibrillation (AF). While PFA-based pulmonary vein isolation (PVI) has been reported to result in extensive isolation of the left atrial (LA) wall, the specific details and its relationship with creatine kinase (CK) and CK-MB levels remain unclear.

40

40

HeartRhythm

MARCH 31, 2025

A novel focal 9mm lattice tip catheter, namely Sphere-9, has recently received regulatory approval and is part of a technology that allows the delivery of either pulsed electric field or radiofrequency energy and incorporates a proprietary 3D electroanatomical mapping system.

40

40